Perspective Therapeutics (CATX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

CATX Perspective Therapeutics

Watchlist

4.3500
+0.2300+5.58%

Close Nov 29 13:00 ET

4.3201
-0.0299-0.69%

Post 16:54 ET

294.01MMarket Cap-2919P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Perspective Therapeutics to Participate in Upcoming Investor Conferences in December
GlobeNewswireNov 27 07:00 ET
Insider Purchase: CEO of $CATX (CATX) Buys 6,600 Shares
Quiver QuantitativeNov 26 07:15 ET
Perspective Therapeutics Downgraded to Neutral From Buy at BofA
Yahoo FinanceNov 26 06:45 ET
Perspective Therapeutics Is Maintained at Outperform by RBC Capital
Dow JonesNov 25 10:55 ET · Ratings
BofA Securities Maintains Perspective Therapeutics(CATX.US) With Hold Rating, Maintains Target Price $6
Moomoo NewsNov 25 10:33 ET · Ratings
B of A Securities Downgrades Perspective Therapeutics to Neutral, Lowers Price Target to $6
BenzingaNov 25 08:05 ET · Ratings

Comments

Jaguar8

Nov 22 13:52

Easy 16% 😉

$Perspective Therapeutics (CATX.US)$

Johnny Mnemonic

Nov 22 10:12

I don't trust nobody
I don't even trust my mind
losing everybody
they can never take my grind

Jaguar8

Nov 21 23:09

On watchlist. Reason: Presentation today. Possible PR tomorrow

$Perspective Therapeutics (CATX.US)$

Stock_Drift

Nov 15 16:17

After Hours Ticks. 5:16pm 11/15🦌

$Scorpius Holdings (SCPX.US)$ $Perspective Therapeutics (CATX.US)$ $Turbo Energy (TURB.US)$ $Adverum Biotechnologies (ADVM.US)$ $NFT Ltd (MI.US)$ $Xylo Technologies (XYLO.US)$ $Lipocine (LPCN.US)$ $Massimo (MAMO.US)$ $China Jo-Jo Drugstores (CJJD.US)$ $Edesa Biotech (EDSA.US)$ $Atara Biotherapeutics (ATRA.US)$ $Eterna Therapeutics (ERNA.US)$ $DDC Enterprise (DDC.US)$
📊⚡️📊

Trytosaveabit

Nov 15 15:13

Watching! Note the dates!

$Perspective Therapeutics (CATX.US)$ Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today released details regarding the upcoming presentation of initial results from the Company-sponsored Phase 1/2a trial of [212Pb]VMT-α-NET at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium t...

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

CATX Perspective Therapeutics

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target